Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Glioblastoma 5Gliosarcoma 4Squamous Cell Carcinoma of Head and Neck 3Glioma 3Brain Neoplasms 3Treatment-Refractory Solid Tumors 2Salivary Gland Neoplasms 2Central Nervous System Neoplasms 2Tongue Neoplasms 1Oligodendroglioma 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Head and Neck Neoplasms 1HPV-Negative Squamous Cell Carcinoma 1Esthesioneuroblastoma, Olfactory 1Ependymoma 1Carcinoma, Non-Small-Cell Lung 1Bites and Stings 1Astrocytoma 1Advanced Solid Tumors 1

Interventions

atezolizumab 2Hydroxyurea 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Treatment-Refractory Solid Tumors × Hydroxyurea × Clear all
NCT07190833 2026-04-09

A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea)

Bionoxx Inc.

Phase 1 Recruiting
27 enrolled
Other solid neoplasm

Treatment-Refractory Solid Tumors

NCT07170592 2026-04-07

A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients

Bionoxx Inc.

Phase 1 Not yet recruiting
24 enrolled
Other solid neoplasm

Treatment-Refractory Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡